Marker Therapeutics, Inc. (MRKR)
Seite 1 von 2 Neuester Beitrag: 25.04.21 00:13 | ||||
Eröffnet am: | 30.04.20 05:47 | von: Chalifmann3 | Anzahl Beiträge: | 28 |
Neuester Beitrag: | 25.04.21 00:13 | von: Nicolempsfa | Leser gesamt: | 9.323 |
Forum: | Hot-Stocks | Leser heute: | 1 | |
Bewertet mit: | ||||
Seite: < 1 | 2 > |
mein alter Tapimmune Thread hat offenbar ausgedient,Tapimmune heisst heute Marker Therapeutics und ich sehe absolut phantastisches Potential,der erste Orphan status kam gestern nach Börsenschluss,und die finanzielle Situation hat sich nach dem merger drastisch verbessert,so lanfsam wird ein Schuh draus,hm ?!!
Cobra,moneyplus und Richiberlin,seid ihr noch dran an dem Teil bzw, investiert ?
MFG
Chali
Würde mich freuen, wenn es dort anders wäre.
Meine Meinung - KEINE Handelsempfehlung.
HOUSTON, May 13, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that updated clinical data from an investigator-sponsored Phase 1/2 trial led by Baylor College of Medicine were selected for presentation during a poster session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. ASCO 2020 will be held virtually from Friday, May 29 through Sunday, May 31, 2020. The data will be presented by lead investigator, Brandon G. Smaglo, M.D., FACP.
Marker Therapeutics, Inc. (PRNewsfoto/Marker Therapeutics, Inc.)
Marker Therapeutics, Inc. (PRNewsfoto/Marker Therapeutics, Inc.)
More
Presentation Details
Title: "A phase I trial targeting advanced or metastatic pancreatic cancer using a combination of standard chemotherapy and adoptively transferred nonengineered, multiantigen specific T cells in the first-line setting (TACTOPS)"
Authors: Smaglo BG, et al.
Session Type: Poster Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract: 4622
Poster: 230
The presentation will be available on demand to ASCO registrants beginning May 29, 2020 at 8:00 a.m. ET. The poster will be available in the Investors section of the Company's website at markertherapeutics.com.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies
Bei Pieris dagegen ist der Fahrplan trotz einiger nicht über die Anfangsphasen weitergeführter Projekte recht eindeutig und sollte mit dem Start der Phase II durch Astrazeneca wieder richtig loslegen.
Meine Meinung - KEINE Handelsempfehlung.
Bei Pieris sind die Ergebnisse ja schon vorgezeichnet und der Kurs dürfte nur auf eine Meldung der Phase 2 durch AstraZeneca warten.
Meine Meinung - KEINE Handelsempfehlung.
--
https://www.markertherapeutics.com/2020/05/...-asco-virtual-annual-m/
MARKER THERAPEUTICS REPORTS INTERIM RESULTS OF ITS MULTITAA-SPECIFIC T CELL THERAPY IN PATIENTS WITH PANCREATIC ADENOCARCINOMA AT THE 2020 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) VIRTUAL ANNUAL MEETING
MAY 29, 2020
...
https://meetinglibrary.asco.org/record/186395/abstract
PR Newswire PR NewswireJune 23, 2020
HOUSTON, June 23, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced today that the United States Adopted Names (USAN) Council has approved "zelenoleucel" as the nonproprietary (generic) name for MT-401, a multi-tumor-associated antigen (MultiTAA)-specific T cell product candidate for the treatment of patients with acute myeloid leukemia (AML) following allogeneic stem cell transplant in both adjuvant and active disease settings.
Marker Therapeutics, Inc. (PRNewsfoto/Marker Therapeutics, Inc.)
Marker Therapeutics, Inc. (PRNewsfoto/Marker Therapeutics, Inc.)
More
"The USAN approval of zelenoleucel as the generic name for MT-401 is another step forward for continued advancement of our therapy," said Peter L. Hoang, President & CEO of Marker Therapeutics. "MT-401, which received Orphan Drug designation from the U.S. FDA in April, has shown clinical benefit in patients with acute myeloid leukemia post stem cell transplant in an investigator-sponsored trial. We are excited about the continued clinical development of zelenoleucel and look forward to initiating our Company-sponsored Phase 2 study in patients with AML following transplant."
About USAN
The United States Adopted Names (USAN) Council is responsible for selecting simple, informative and unique nonproprietary (generic) drug names. The USAN Council establishes logical nomenclature classifications based on pharmacological and/or chemical relationships. In addition to one member-at-large and a Food and Drug Administration (FDA) liaison, the council consists of one representative from each of the following: The American Medical Association, United States Pharmacopeia (USP) and the American Pharmacists Association.
About MultiTAA-Specific T Cell Therapy
Marker's Multi-Tumor-Associated Antigen Targeted (MultiTAA) platform is a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient's blood capable of recognizing a broad range of tumor antigens. In early clinical trials, the multi-antigen approach has been well-tolerated and shown to enhance tumor destroying capability of T cells. It is one of the first therapies to consistently demonstrate epitope-spreading – inducing the patient's own T cells to expand, potentially contributing to a lasting anti-tumor effect. Unlike other cell therapies which require pre-conditioning regimens and hospitalization, MultiTAA-specific T cells are designed to be administered in an outpatient setting.
PR Newswire PR Newswire•June 30, 2020
-- Facility expected to be built by year-end, fully operational in 2021 --
HOUSTON, June 30, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it has executed a lease agreement to establish a cGMP manufacturing facility in Houston, TX, in an area near the George Bush Intercontinental Airport. The facility will allow production according to U.S. Food and Drug Administration (FDA) guidelines and is designed to be scalable using modular processes. The facility is expected to be completed by year-end and operational in 2021.
Marker Therapeutics, Inc. (PRNewsfoto/Marker Therapeutics, Inc.)
Marker Therapeutics, Inc. (PRNewsfoto/Marker Therapeutics, Inc.)
More
"We are committed to the rapid advancement of Marker's MultiTAA-specific T cell therapies, which have demonstrated impressive responses in clinical studies across both hematological and solid tumors," said Peter L. Hoang, President & CEO of Marker Therapeutics. "With the build-out of our own internal manufacturing capabilities, we will have the flexibility to support our AML trial, and future hematological and solid tumor trials, as well as the potential commercialization of our products."
The facility has approximately 48,500 feet and will provide space for clinical manufacturing and quality functions upon completion. Marker will continue to manufacture its MultiTAA-specific T cell therapy at the Baylor College of Medicine to support the Company-sponsored AML trial until the in-house cGMP manufacturing facility is operational.
Commented Anthony Kim, Marker's Chief Financial Officer: "Commencing the build-out of our internal cGMP facility strategically fits Marker's expansion plans and is an exciting next step as we initiate our first Company-sponsored clinical trial in patients with AML following transplant.
MARCH 3, 2021
"TOPLINE READOUT OF ACTIVE DISEASE GROUP IN AML TRIAL EXPECTED IN Q1 2022
Houston, TX – March 3, 2021– Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced it has treated the first patient in the Company’s Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate. The trial is enrolling patients with acute myeloid leukemia (AML) following an allogeneic stem cell transplant in both the adjuvant and active disease settings..."
https://www.markertherapeutics.com/2021/03/...g-stem-cell-transplant/
--
Startschuss für die nächste Welle !?
https://www.markertherapeutics.com/2021/03/...-and-financial-results/
Kurs knickt ein..
https://www.ariva.de/news/...nounces-proposed-public-offering-9252411